Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow

Arrowhead Pharmaceuticals, Inc. (ARWR) shared interim results from its ARO-MAPT clinical trial and provided an update on its TRiM CNS delivery platform. The company's pipeline focuses on treatments for rare diseases and cancer.

Want to stay up to date with the world events at sea or at home?

Explore Navvyx News - the best News app for seafarers.

Join Navvyx - it's Free